Literature DB >> 4054202

Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.

V Trillet, M Lakhal, J Lang, E Perrin-Fayolle, Q Timour Chah, D Fière, G Faucon.   

Abstract

In 6 patients with acute myeloblastic leukaemia, daunorubicin was assayed in leukaemic cells from peripheral blood or bone marrow. The cells were separated from red blood cells and granulocytes by centrifugation on a Ficoll-Isopac gradient. The assay was performed by high performance liquid chromatography. Daunorubicin concentrations in peripheral leukaemic cells, 2 hours after the end of the infusion, were much higher than in plasma, the cell/plasma concentration ratio reaching about 350 and rising to almost 700 at 24 h. At that time, drug concentrations were even higher in the bone marrow leukaemic cells. The value of the assay of daunorubicin in cells as method for monitoring therapy is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4054202     DOI: 10.1007/BF00547382

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Antitumor activity of some derivatives of daunorubicin at the amino and methyl ketone functions.

Authors:  K Yamamoto; E M Acton; D W Henry
Journal:  J Med Chem       Date:  1972-08       Impact factor: 7.446

2.  Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts.

Authors:  G Noel; C Peterson; A Trouet; P Tulkens
Journal:  Eur J Cancer       Date:  1978-04       Impact factor: 9.162

3.  Extraction and quantification of daunomycin and doxorubicin in tissues.

Authors:  J F Strauss; R L Kitchens; V W Patrizi; E P Frenkel
Journal:  J Chromatogr       Date:  1980-11-14

4.  The mechanism for cellular uptake, storage and release of daunorubicin. Studies on fibroblasts in culture.

Authors:  C Peterson; R Baurain; A Trouet
Journal:  Biochem Pharmacol       Date:  1980-06-15       Impact factor: 5.858

5.  DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.

Authors:  Y J Schneider; R Baurain; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  [Daunorubicin and blood cells. Uptake and metabolism].

Authors:  J Ritter; F Durand; D Fiere; J L Brazier; G Faucon
Journal:  Therapie       Date:  1984 Mar-Apr       Impact factor: 2.070

7.  Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.

Authors:  D S Chervinsky; J J Wang
Journal:  J Med       Date:  1976

8.  Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.

Authors:  C Paul; R Baurain; G Gahrton; C Peterson
Journal:  Cancer Lett       Date:  1980-06       Impact factor: 8.679

  8 in total
  4 in total

1.  Doxorubicin concentration time course in the myocardium after single administration to the dog. Possible role in the cardiac effects.

Authors:  Q Timour; P Nony; J Lang; M Lakhal; V Trillet; G Faucon
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Doxorubicin concentrations in plasma and myocardium and their respective roles in cardiotoxicity.

Authors:  Q Timour; P Nony; J Lang; M Lakhal; V Trillet; G Faucon
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

3.  Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.

Authors:  Savitha Varatharajan; John C Panetta; Ajay Abraham; Sreeja Karathedath; Ezhilpavai Mohanan; Kavitha M Lakshmi; Nancy Arthur; Vivi M Srivastava; Sandeep Nemani; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-13       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.